SCHEMBL1473665

SCHEMBL1473665

CCOC(=O)C1CC1(C)c1cc(F)c(C(C)(C)C(F)(F)F)c(F)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.33
HIF1A Q16665 1/20 0.33
KCNN4 O15554 1/20 0.32
ALDH1A1 P00352 7/20 0.32
TDP1 Q9NUW8 1/20 0.32
RORC P51449 3/20 0.31
NR1I2 O75469 1/20 0.31
KDM4E B2RXH2 2/20 0.31
MEN1 O00255 2/20 0.31
HPGD P15428 2/20 0.31
KMT2A Q03164 2/20 0.31
GAA P10253 1/20 0.31
HSD17B10 Q99714 1/20 0.31
PSEN1 P49768 1/20 0.30
PSEN2 P49810 1/20 0.30
APH1B Q8WW43 1/20 0.30
NCSTN Q92542 1/20 0.30
APH1A Q96BI3 1/20 0.30
PSENEN Q9NZ42 1/20 0.30
LGMN Q99538 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1473609 0.89 ALDH1A1 (0.34) MAPTKCNN4ALDH1A1TDP1KDM4E
SCHEMBL1473932 0.82 CCR2 (0.33)
SCHEMBL1474012 0.81 RORC (0.41) MAPTHIF1AALDH1A1RORCNR1I2
SCHEMBL1474226 0.79 EPHX2 (0.42) KCNN4ALDH1A1TDP1KDM4E
SCHEMBL1474477 0.74 ALDH1A1 (0.46) MAPTALDH1A1RORCNR1I2KDM4E
SCHEMBL1474209 0.73 CA1 (0.34) MAPTALDH1A1TDP1KMT2ATSHR
SCHEMBL9820733 0.72 MEN1 (0.45) MAPTALDH1A1RORCNR1I2MEN1
SCHEMBL1473939 0.72 POLB (0.47) ALDH1A1MEN1KMT2ALMNAPOLB
SCHEMBL23020811 0.71 OPRM1 (0.43) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL15978556 0.71 L3MBTL1 (0.49) MAPTALDH1A1RORCNR1I2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861359-B1 N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN PFIZER (US) 2012-11-14 EP disclosed
US-7915448-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2011-03-29 US disclosed
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS PFIZER INC 2010-02-11 US disclosed
US-7622589-B2 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER INC. (US) 2009-11-24 US disclosed
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists PFIZER, INC. 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211741-A1 Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists CNR1, HVCN1, CNR2 MAPT 4877/4885HIF1A 681/4885KCNN4 361/4885
US-20100035880-A1 SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS CNR1, HVCN1, CNR2 MAPT 4877/4885HIF1A 686/4885KCNN4 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.